Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer
Top Cited Papers
- 8 August 2006
- journal article
- research article
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 45 (11) , 1033-1040
- https://doi.org/10.1002/gcc.20366
Abstract
Breast cancer is a leading cause of cancer‐death among women, where the clinicopathological features of tumors are used to prognosticate and guide therapy. DNA copy number alterations (CNAs), which occur frequently in breast cancer and define key pathogenetic events, are also potentially useful prognostic or predictive factors. Here, we report a genome‐wide array‐based comparative genomic hybridization (array CGH) survey of CNAs in 89 breast tumors from a patient cohort with locally advanced disease. Statistical analysis links distinct cytoband loci harboring CNAs to specific clinicopathological parameters, including tumor grade, estrogen receptor status, presence of TP53 mutation, and overall survival. Notably, distinct spectra of CNAs also underlie the different subtypes of breast cancer recently defined by expression‐profiling, implying these subtypes develop along distinct genetic pathways. In addition, higher numbers of gains/losses are associated with the “basal‐like” tumor subtype, while high‐level DNA amplification is more frequent in “luminal‐B” subtype tumors, suggesting also that distinct mechanisms of genomic instability might underlie their pathogenesis. The identified CNAs may provide a basis for improved patient prognostication, as well as a starting point to define important genes to further our understanding of the pathobiology of breast cancer. This article contains Supplementary Material available at http://www.interscience.wiley.com/jpages/1045‐2257/suppmat.Keywords
This publication has 32 references indexed in Scilit:
- Transcriptional regulation and transformation by Myc proteinsNature Reviews Molecular Cell Biology, 2005
- Overview of tyrosine kinase inhibitors in clinical breast cancerEndocrine-Related Cancer, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- The future of breast cancer: the role of prognostic factorsBreast Cancer Research and Treatment, 2005
- Prognostic Relevance of Gene Amplifications and Coamplifications in Breast CancerCancer Research, 2004
- “Good Old” clinical markers have similar power in breast cancer prognosis as microarray gene expression profilersEuropean Journal Of Cancer, 2004
- Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast CancerJNCI Journal of the National Cancer Institute, 2003
- The Stanford Microarray Database: data access and quality assessment toolsNucleic Acids Research, 2003
- Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survivalProceedings of the National Academy of Sciences, 2001
- Amplification and Deletion of Topoisomerase IIα Associate with ErbB-2 Amplification and Affect Sensitivity to Topoisomerase II Inhibitor Doxorubicin in Breast CancerThe American Journal of Pathology, 2000